Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 10, 2010, Pages 1073-1090

  Linger, Rachel M A ^a   Keating, Amy K ^a   Earp, H Shelton ^b   Graham, Douglas K ^a  

^a Children's Hospital Colorado   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Animal models; Apoptosis; Astrocytoma; Breast cancer; Cell migration invasion; Cell survival; Chemosensitivity; Glioblastoma multiforme; Glioma; Human; Metastasis; Non small cell lung cancer; Protein kinase inhibitor; Receptor tyrosine kinase; Signal transduction; Targeted therapy

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; AMUVATINIB; AXL FC FUSION PROTEIN; AXL RECEPTOR TYROSINE KINASE; BEVACIZUMAB; BMS 777607; BOSUTINIB; CETUXIMAB; ERLOTINIB; FORETINIB; GEFITINIB; HYBRID PROTEIN; LAPATINIB; MER FC FUSION PROTEIN; MER RECEPTOR TYROSINE KINASE; MONOCLONAL ANTIBODY; MP 470; PF 5208763; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; R 428; RAPAMYCIN; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; XL 880;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CELL INVASION; CELL MIGRATION; CELL SURVIVAL; CHEMOSENSITIVITY; CHRONIC MYELOID LEUKEMIA; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; ENDOMETRIUM CARCINOMA; ENZYME ACTIVATION; ENZYME INHIBITION; ESOPHAGUS CANCER; GLIOBLASTOMA; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; KIDNEY CARCINOMA; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; METASTASIS; MICROENVIRONMENT; NEUROENDOCRINE TUMOR; NONHUMAN; ONCOGENE; PHENOTYPE; PROGNOSIS; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; STOMACH CARCINOMA; STROMA CELL; THROMBOPHILIA; TUMOR CELL; VALIDATION PROCESS;

CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; ONCOGENE PROTEINS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 77957092501     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2010.515980     Document Type: Review

References (143)

1. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001;15:1311-1333
2. Sleijfer S, Wiemer E, Verweij J. Drug Insight: gastrointestinal stromal tumors (GIST)-the solid tumor model for cancer-specific treatment. Nat Clin Pract Oncol 2008;5:102-111
3. Blagosklonny MV. Analysis of FDA approved anticancer drugs reveals the future of cancer therapy. Cell Cycle 2004;3:1035-1042
4. Sridhara R, Johnson JR, Justice R, et al. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007. J Natl Cancer Inst 2010;102:230-243
5. Graham DK, Dawson TL, Mullaney DL, et al. Cloning and mRNA expression analysis of a novel human protooncogene, c-mer. Cell Growth Differ 1994;5:647-657
6. OBryan JP, Frye RA, Cogswell PC, et al. Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 1991;11:5016-5031
7. Graham DK, Salzberg DB, Kurtzberg J, et al. Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin Cancer Res 2006;12:2662-2669
8. Hong CC, Lay JD, Huang JS, et al. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett 2008;268:314-324.
9. Keating AK, Salzberg DB, Sather S, et al. Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase. Oncogene 2006;25:6092-6100
10. Linger RMA, DeRyckere D, Brandao L, et al. Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia. Blood 2009;114:2678-2687
11. Lee-Sherick AB, Linger RMA, Gore L, et al. Novel targeted therapies in pediatric acute lymphoblastic leukemia. Br J Haematol 2010; In Press
12. Rochlitz C, Lohri A, Bacchi M, et al. Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). Leukemia 1999;13:1352-1358
13. Chen J, Carey K, Godowski PJ. Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation. Oncogene 1997;14:2033-2039
14. Fisher PW, Brigham-Burke M, Wu SJ, et al. A novel site contributing to growth-arrest-specific gene 6 binding to its receptors as revealed by a human monoclonal antibody. Biochem J 2005;387:727-735
15. Nagata K, Ohashi K, Nakano T, et al. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem 1996;271:30022-30027
16. Prasad D, Rothlin CV, Burrola P, et al. TAM receptor function in the retinal pigment epithelium. Mol Cell Neurosci 2006;33:96-108
17. Linger RMA, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 2008;100:35-83
18. Angelillo-Scherrer A, Burnier L, Lambrechts D, et al. Role of Gas6 in erythropoiesis and anemia in mice. J Clin Invest 2008;118:583-596
19. Tang H, Chen S, Wang H, et al. TAM receptors and the regulation of erythropoiesis in mice. Haematologica 2009;94:326-334
20. Behrens EM, Gadue P, Gong SY, et al. The mer receptor tyrosine kinase: expression and function suggest a role in innate immunity. Eur J Immunol 2003;33:2160-2167
21. Caraux A, Lu Q, Fernandez N, et al. Natural killer cell differentiation driven by Tyro3 receptor tyrosine kinases. Nat Immunol 2006;7:747-754
22. Gjerdrum C, Tiron C, Hoiby T, et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci USA 2010;107:1124-1129
23. Shieh YS, Lai CY, Kao YR, et al. Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia 2005;7:1058-1064
24. Koorstra JB, Karikari CA, Feldmann G, et al. The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther 2009;8:618-626
25. Wu CW, Li AF, Chi CW, et al. Clinical significance of AXL kinase family in gastric cancer. Anticancer Res 2002;22:1071-1078
26. Hafizi S, Dahlback B. Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J 2006;273:5231-5244
27. Manfioletti G, Brancolini C, Avanzi G, Schneider C. The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to Protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol 1993;13:4976-4985
28. Sainaghi PP, Castello L, Bergamasco L, et al. Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol 2005;204:36-44
29. Sawabu T, Seno H, Kawashima T, et al. Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway. Mol Carcinog 2007;46:155-164
30. Eisenman K, Sather S, McGranahan A, et al. Mer receptor tyrosine kinase as a potential novel target in acute myeloid leukemia. Pediatr Blood Cancer 2010;54:790
31. Lee WP, Wen Y, Varnum B, Hung MC. Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis. Oncogene 2002;21:329-336
32. Keating AK, Kim GK, Jones AE, et al. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther 2010;9:1298-1307
33. Liu L, Greger J, Shi H, et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 2009;69:6871-6878
34. Qi W, Cooke LS, Stejskal A, et al. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC Cancer 2009;9:142
35. Bose R, Molina H, Patterson AS, et al. Phosphoproteomic analysis of Her2/neu signaling and inhibition. Proc Natl Acad Sci USA 2006;103:9773-9778
36. Komurov K, Padron D, Cheng T, et al. Comprehensive mapping of the human kinome to EGF receptor signaling. J Biol Chem 2010;285:21134-21142
37. Wu YM, Robinson DR, Kung HJ. Signal pathways in up-regulation of chemokines by tyrosine kinase MER/NYK in prostate cancer cells. Cancer Res 2004;64:7311-7320
38. Holland SJ, Pan A, Franci C, et al. R428, a Selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 2010;70:1544-1554
39. Holland SJ, Powell MJ, Franci C, et al. Multiple roles for the receptor tyrosine kinase Axl in tumor formation. Cancer Res 2005;65:9294-9303
40. Mudduluru G, Vajkoczy P, Allgayer H. Myeloid zinc finger 1 induces migration, invasion, and in vivo metastasis through Axl gene expression in solid cancer. Mol Cancer Res 2010;8:159-169
41. Le Mee S, Fromigue O, Marie PJ. Sp1/Sp3 and the myeloid zinc finger gene MZF1 regulate the human N-cadherin promoter in osteoblasts. Exp Cell Res 2005;302:129-142
42. Tai KY, Shieh YS, Lee CS, et al. Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1. Oncogene 2008;27:4044-4055
43. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-466
44. Van Meir EG, Hadjipanayis CG, Norden AD, et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010;60:166-193
45. Libermann TA, Nusbaum HR, Razon N, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985;313:144-147
46. Hlobilkova A, Ehrmann J, Sedlakova E, et al. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression? Neoplasma 2007;54:334-341
47. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501
48. Hartmann C, Bartels G, Gehlhaar C, et al. PIK3CA mutations in glioblastoma multiforme. Acta Neuropathol 2005;109:639-642
49. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-1947
50. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554 (Pubitemid 38541907)
51. Wang SI, Puc J, Li J, et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 1997;57:4183-4186
52. Wang H, Zhang W, Huang HJ, et al. Analysis of the activation status of Akt, NFkB, and Stat3 in human diffuse gliomas. Lab Invest 2004;84(8):941-951
53. Mizoguchi M, Betensky RA, Batchelor TT, et al. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 2006;65:1181-1188
54. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318:287-290
55. Hutterer M, Knyazev P, Abate A, et al. Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res 2008;14:130-138.
56. Vajkoczy P, Knyazev P, Kunkel A, et al. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci USA 2006;103:5799-5804.
57. Jones AE, Le J, Keating AK. Mer receptor tyrosine kinase affects glioblastoma multiforme migration [abstract 17]. FASEB SRC: receptor tyrosine kinases: biology and cancer 2010; Carefree, Arizona, USA; 2010
58. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol 2007;25:561-570
59. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers - a different disease. Nat Rev Cancer 2007;7:778-790
60. Altekruse SF, Kosary CL, Krapcho M, et al. SEER cancer statistics review, 1975-2007. based on November 2009 SEER data submission ed. National Cancer Institute, Bethesda, MD; 2010
61. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550
62. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128
63. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957
64. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967
65. Rothenberg ML. ALK: a promising new target in the treatment of NSCLC. AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Prospects for Personalized Prevention and Therapy. Coronado, CA, USA; 2010
66. Wimmel A, Glitz D, Kraus A, et al. Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion. Eur J Cancer 2001;37:2264-2274
67. Wimmel A, Rohner I, Ramaswamy A, et al. Synthesis and secretion of the anticoagulant protein S and coexpression of the Tyro3 receptor in human lung carcinoma cells. Cancer 1999;86:43-49
68. Linger R.M.A., Middleton D.H.G., Migdall J, et al. Mer and Axl receptor tyrosine kinases are novel therapeutic targets in NSCLC. AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer - Prospects for Personalized Prevention and Therapy. Coronado, CA; 2010
69. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-1203
70. Li Y, Ye X, Tan C, et al. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene 2009;28:3442-3455
71. Gluz O, Liedtke C, Gottschalk N, et al. Triple-negative breast cancer - current status and future directions. Ann Oncol 2009;20:1913-1927
72. Berclaz G, Altermatt HJ, Rohrbach V, et al. Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast. Ann Oncol 2001;12:819-824
73. Meric F, Lee WP, Sahin A, et al. Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res 2002;8:361-367
74. Tavazoie SF, Alarcon C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008;451:147-152.
75. Mo R, Tony Zhu Y, Zhang Z, et al. GAS6 is an estrogen-inducible gene in mammary epithelial cells. Biochem Biophys Res Commun 2007;353:189-194
76. Richer JK, Jacobsen BM, Manning NG, et al. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 2002;277:5209-5218
77. Mc Cormack O, Chung WY, Fitzpatrick P, et al. Growth arrest-specific gene 6 expression in human breast cancer. Br J Cancer 2008;98:1141-1146
78. Abba MC, Fabris VT, Hu Y, et al. Identification of novel amplification gene targets in mouse and human breast cancer at a syntenic cluster mapping to mouse ch8A1 and human ch13q34. Cancer Res 2007;67:4104-4112
79. Zhang YX, Knyazev PG, Cheburkin YV, et al. AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res 2008;68:1905-1915
80. Zantek ND, Walker-Daniels J, Stewart J, et al. MCF-10A-NeoST: a new cell system for studying cell-ECM and cell-cell interactions in breast cancer. Clin Cancer Res 2001;7:3640-3648
81. Lemke G, Lu Q. Macrophage regulation by Tyro 3 family receptors. Curr Opin Immunol 2003;15:31-36
82. Lahiry P, Torkamani A, Schork NJ, Hegele RA. Kinase mutations in human disease: interpreting genotype-phenotype relationships. Nat Rev Genet 2010;11:60-74
83. Eder JP, Shapiro GI, Appleman LJ, et al. A Phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 2010;16(13):3507-3516
84. Srinivasan R, Choueiri T, Vaishampayan U, et al. A phase II study of the dual MET-VEGFR2 inhibitor GSK1363089 (Formerly XL880) in patients with papillary renal carcinoma (PRC). Annual Meeting of the American Society of Clinical Oncology. Chicago, Illinois, USA; 2008. J Clin Oncol 2008;26(20 Suppl):abstract 5103
85. Vollrath D, Feng W, Duncan JL, et al. Correction of the retinal dystrophy phenotype of the RCS rat by viral gene transfer of Mertk. Proc Natl Acad Sci USA 2001;98:12584-12589
86. Mahadevan D, Cooke L, Riley C, et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 2007;26:3909-3919.
87. Quintas-Cardama A, Kantarjian H, Cortes J. Imatinib and beyond - exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 2009;6:535-543
88. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009;27:469-471
89. Schroeder GM, An Y, Cai ZW, et al. Discovery of N-(4-(2-amino-3- chloropyridin-4-yloxy)-3-fluorophenyl)-4- ethoxy-1-(4-fluor ophenyl)-2-oxo-1,2- dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J Med Chem 2009;52:1251-1254
90. Huang X, Finerty P Jr, Walker JR, et al. Structural insights into the inhibited states of the Mer receptor tyrosine kinase. J Struct Biol 2009;165:88-96
91. Ye X, Li Y, Stawicki S, et al. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 2010: published online 5 July 2010, doi: 10.1038/onc.2010.268
92. Brandao L, Molk D, Sather S, Graham DK. Inhibition of Mer as a novel therapeutic strategy in acute lymphoblastic leukemia [abstract 105]. Keystone Symposia: New Paradigms in Cancer Therapeutics; 2010 23 - 28 March 2010; Victoria, British Columbia, Canada; 2010
93. Anwar A, Keating AK, Joung D, et al. Mer tyrosine kinase (MerTK) promotes macrophage survival following exposure to oxidative stress. J Leukoc Biol 2009;86:73-79
94. Sather S, Kenyon KD, Lefkowitz JB, et al. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood 2007;109:1026-1033
95. Mudduluru G, Allgayer H. The human receptor tyrosine kinase Axl gene - promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation. Biosci Rep 2008;28:161-176
96. Wong CC, Lee WM. The proximal cis-acting elements Sp1, Sp3 and E2F regulate mouse mer gene transcription in Sertoli cells. Eur J Biochem 2002;269:3789-3800
97. Margareto J, Leis O, Larrarte E, et al. DNA copy number variation and gene expression analyses reveal the implication of specific oncogenes and genes in GBM. Cancer Invest 2009;27:541-548
98. Loges S, Schmidt T, Tjwa M, et al. Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood 2010;115:2264-2273
99. Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003;4:75-85
100. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-792 (Pubitemid 40271173)
101. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2(3):e73
102. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104:20932-20937
103. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043
104. Grosso S, Puissant A, Dufies M, et al. Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors. Mol Cancer Ther 2009;8:1924-1933
105. Lay JD, Hong CC, Huang JS, et al. Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer Res 2007;67:3878-3887
106. Macleod K, Mullen P, Sewell J, et al. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res 2005;65:6789-6800.
107. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 2010;10:130-137
108. Xu AM, Huang PH. Receptor tyrosine kinase coactivation networks in cancer. Cancer Res 2010;70:3857-3860
109. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792
110. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-1552
111. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial-INTACT 1. J Clin Oncol 2004;22:777-784 (Pubitemid 41103588)
112. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794 (Pubitemid 41103589)
113. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899
114. Cappuzzo F, Gregorc V, Rossi E, et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 2003;21:2658-2663
115. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-3807
116. Fong T, Morgensztern D, Govindan R. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer. J Thorac Oncol 2008;3:303-310
117. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139
118. Nakano T, Tani M, Ishibashi Y, et al. Biological properties and gene expression associated with metastatic potential of human osteosarcoma. Clin Exp Metastasis 2003;20:665-674
119. Craven RJ, Xu LH, Weiner TM, et al. Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer 1995;60:791-797
120. Sun WS, Fujimoto J, Tamaya T. Coexpression of growth arrest-specific gene 6 and receptor tyrosine kinases Axl and Sky in human uterine endometrial cancers. Ann Oncol 2003;14:898-906 (Pubitemid 36827206)
121. Nemoto T, Ohashi K, Akashi T, et al. Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology 1997;65:195-203
122. Chung BI, Malkowicz SB, Nguyen TB, et al. Expression of the proto-oncogene Axl in renal cell carcinoma. DNA Cell Biol 2003;22:533-540
123. Gustafsson A, Martuszewska D, Johansson M, et al. Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res 2009;15:4742-4749
124. Tsou AP, Wu KM, Tsen TY, et al. Parallel hybridization analysis of multiple protein kinase genes: identification of gene expression patterns characteristic of human hepatocellular carcinoma. Genomics 1998;50:331-340
125. Ek S, Hogerkorp CM, Dictor M, et al. Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Res 2002;62:4398-4405
126. Sun W, Fujimoto J, Tamaya T. Coexpression of Gas6/Axl in human ovarian cancers. Oncology 2004;66:450-457
127. Evans CO, Young AN, Brown MR, et al. Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab 2001;86:3097-3107
128. Mahajan NP, Whang YE, Mohler JL, Earp HS. Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer Res 2005;65:10514-10523
129. Jacob AN, Kalapurakal J, Davidson WR, et al. A receptor tyrosine kinase, UFO/Axl, and other genes isolated by a modified differential display PCR are overexpressed in metastatic prostatic carcinoma cell line DU145. Cancer Detect Prev 1999;23:325-332
130. Khan J, Bittner ML, Saal LH, et al. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci USA 1999;96:13264-13269
131. van Ginkel PR, Gee RL, Shearer RL, et al. Expression of the receptor tyrosine kinase Axl promotes ocular melanoma cell survival. Cancer Res 2004;64:128-134
132. Gyorffy B, Lage H. A web-based data warehouse on gene expression in human malignant melanoma. J Invest Dermatol 2007;127:394-399
133. Quong RY, Bickford ST, Ing YL, et al. Protein kinases in normal and transformed melanocytes. Melanoma Res 1994;4:313-319
134. Lin WC, Li AF, Chi CW, et al. tie-1 protein tyrosine kinase: a novel independent prognostic marker for gastric cancer. Clin Cancer Res 1999;5:1745-1751
135. Tanaka K, Nagayama Y, Nakano T, et al. Expression profile of receptor-type protein tyrosine kinase genes in the human thyroid. Endocrinology 1998;139:852-858
136. Ito M, Nakashima M, Nakayama T, et al. Expression of receptor-type tyrosine kinase, Axl, and its ligand, Gas6, in pediatric thyroid carcinomas around chernobyl. Thyroid 2002;12:971-975
137. Ito T, Ito M, Naito S, et al. Expression of the Axl receptor tyrosine kinase in human thyroid carcinoma. Thyroid 1999;9:563-567
138. Braunger J, Schleithoff L, Schulz AS, et al. Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site. Oncogene 1997;14:2619-2631
139. Fridell YW, Jin Y, Quilliam LA, et al. Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase. Mol Cell Biol 1996;16:135-145
140. Georgescu MM, Kirsch KH, Shishido T, et al. Biological effects of c-Mer receptor tyrosine kinase in hematopoietic cells depend on the Grb2 binding site in the receptor and activation of NF-kappaB. Mol Cell Biol 1999;19:1171-1181
141. Ling L, Templeton D, Kung HJ. Identification of the major autophosphorylation sites of Nyk/Mer, an NCAM-related receptor tyrosine kinase. J Biol Chem 1996;271:18355-18362
142. Pao-Chun L, Chan PM, Chan W, Manser E. Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is mediated by Grb2: an analysis of ACK1 effects on Axl signaling. J Biol Chem 2009;284:34954-34963
143. Liu Y, Karaca M, Zhang Z, et al. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases. Oncogene 2010;29:3208-3216